Literature DB >> 19585114

Efficacy of 18F-FDG PET/CT in the evaluation of patients with recurrent cervical carcinoma.

Erik Mittra1, Tarek El-Maghraby, Cesar A Rodriguez, Andrew Quon, I Ross McDougall, Sanjiv S Gambhir, Andrei Iagaru.   

Abstract

PURPOSE: Only a limited number of studies have evaluated the efficacy of 18F-FDG PET/CT for recurrent cervical carcinoma, which this study seeks to expand upon.
METHODS: This is a retrospective study of 30 women with cervical carcinoma who had a surveillance PET/CT after initial therapy. Sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were calculated using a 2 × 2 contingency table with pathology results (76%) or clinical follow-up (24%) as the gold standard. The Wilson score method was used to perform 95% confidence interval estimations.
RESULTS: The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of PET/CT for the detection of local recurrence at the primary site were 93, 93, 93, 86, and 96%, respectively. The same values for the detection of distant metastases were 96, 95, 95, 96, and 95%, respectively. Seventy-one percent of the scans performed in symptomatic patients showed true-positive findings. In comparison, 44% of scans performed in asymptomatic patients showed true-positive findings. But, all patients subsequently had a change in their management based on the PET/CT findings such that the effect was notable. The maximum standardized uptake value ranged from 5 to 28 (average: 13 ± 7) in the primary site and 3 to 23 (average: 8 ± 4) in metastases which were significantly different (p = 0.04).
CONCLUSION: This study demonstrates favorable efficacy of 18F-FDG PET/CT for identification of residual/recurrent cervical cancer, as well as for localization of distant metastases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19585114      PMCID: PMC4157596          DOI: 10.1007/s00259-009-1206-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  29 in total

Review 1.  Radiology in invasive cervical cancer.

Authors:  H Hricak; K K Yu
Journal:  AJR Am J Roentgenol       Date:  1996-11       Impact factor: 3.959

2.  Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence.

Authors:  Hyun Hoon Chung; Hoenil Jo; Won Jun Kang; Jae Weon Kim; Noh-Hyun Park; Yong-Sang Song; June-Key Chung; Soon-Beom Kang; Hyo-Pyo Lee
Journal:  Gynecol Oncol       Date:  2006-10-16       Impact factor: 5.482

3.  Post-therapy surveillance of patients with uterine cancers: value of integrated FDG PET/CT in the detection of recurrence.

Authors:  Sandro Sironi; Maria Picchio; Claudio Landoni; Stefania Galimberti; Mauro Signorelli; Valentino Bettinardi; Patrizia Perego; Costantino Mangioni; Cristina Messa; Ferruccio Fazio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11-16       Impact factor: 9.236

4.  The role of hybrid PET/CT in the evaluation of patients with cervical cancer.

Authors:  Amnon Amit; Dan Beck; Lior Lowenstein; Offer Lavie; Rachel Bar Shalom; Zohar Kedar; Ora Israel
Journal:  Gynecol Oncol       Date:  2005-11-02       Impact factor: 5.482

5.  The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study.

Authors:  Annika Loft; Anne Kiil Berthelsen; Henrik Roed; Christian Ottosen; Lene Lundvall; Jens Knudsen; Lotte Nedergaard; Liselotte Højgaard; Svend Aage Engelholm
Journal:  Gynecol Oncol       Date:  2007-05-07       Impact factor: 5.482

6.  Defining the priority of using 18F-FDG PET for recurrent cervical cancer.

Authors:  Tzu-Chen Yen; Lai-Chu See; Ting-Chang Chang; Kuan-Gen Huang; Koon-Kwan Ng; Simon G Tang; Yu-Chen Chang; Swei Hsueh; Chien-Sheng Tsai; Ji-Hong Hong; Cheng-Tao Lin; Angel Chao; Shih-Ya Ma; Wuu-Jyh Lin; Ying-Kai Fu; Chi-Chen Fan; Chyong-Huey Lai
Journal:  J Nucl Med       Date:  2004-10       Impact factor: 10.057

7.  Squamous cell carcinoma antigen, tumor-associated trypsin inhibitor, and carcinoembryonic antigen for monitoring cervical cancer.

Authors:  D Pectasides; N Economides; J Bourazanis; P Pozadzizou; L Gogou; P Koutsiouba; A Athanassiou
Journal:  Am J Clin Oncol       Date:  1994-08       Impact factor: 2.339

8.  "Anatometabolic" tumor imaging: fusion of FDG PET with CT or MRI to localize foci of increased activity.

Authors:  R L Wahl; L E Quint; R D Cieslak; A M Aisen; R A Koeppe; C R Meyer
Journal:  J Nucl Med       Date:  1993-07       Impact factor: 10.057

9.  Recurrent cervical carcinoma after radical hysterectomy.

Authors:  D M Larson; L J Copeland; C A Stringer; D M Gershenson; J M Malone; C L Edwards
Journal:  Gynecol Oncol       Date:  1988-07       Impact factor: 5.482

Review 10.  PET/CT and cross sectional imaging of gynecologic malignancy.

Authors:  Revathy B Iyer; Aparna Balachandran; Catherine E Devine
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

View more
  17 in total

1.  Identification of Distant Metastatic Disease in Uterine Cervical and Endometrial Cancers with FDG PET/CT: Analysis from the ACRIN 6671/GOG 0233 Multicenter Trial.

Authors:  Michael S Gee; Mostafa Atri; Andriy I Bandos; Robert S Mannel; Michael A Gold; Susanna I Lee
Journal:  Radiology       Date:  2017-11-29       Impact factor: 11.105

2.  Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT studies for the diagnosis of uterine cancer recurrence.

Authors:  Kazuhiro Kitajima; Kayo Suzuki; Yuji Nakamoto; Yumiko Onishi; Setsu Sakamoto; Michio Senda; Masato Kita; Kazuro Sugimura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-04-13       Impact factor: 9.236

3.  Detection of distant metastatic disease by positron emission tomography with 18F-fluorodeoxyglucose (FDG-PET) at initial staging of cervical carcinoma.

Authors:  Alexander Lin; Sirui Ma; Farrokh Dehdashti; Stephanie Markovina; Julie Schwarz; Barry Siegel; Matthew Powell; Perry Grigsby
Journal:  Int J Gynecol Cancer       Date:  2019-02-09       Impact factor: 3.437

4.  Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma.

Authors:  Amandine Pallardy; Caroline Bodet-Milin; Aurore Oudoux; Loïc Campion; Emmanuelle Bourbouloux; Christine Sagan; Catherine Ansquer; Aude Testard; Isabelle Resche; Boumédiène Bridji; Françoise Kraeber-Bodéré; Caroline Rousseau
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-20       Impact factor: 9.236

5.  Comparison of 18F-FDG PET/MRI and MRI alone for whole-body staging and potential impact on therapeutic management of women with suspected recurrent pelvic cancer: a follow-up study.

Authors:  Lino M Sawicki; Julian Kirchner; Johannes Grueneisen; Verena Ruhlmann; Bahriye Aktas; Benedikt M Schaarschmidt; Michael Forsting; Ken Herrmann; Gerald Antoch; Lale Umutlu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-21       Impact factor: 9.236

6.  The role of PET/CT in cervical cancer.

Authors:  Fernanda G Herrera; John O Prior
Journal:  Front Oncol       Date:  2013-02-26       Impact factor: 6.244

7.  Diagnostic performance of contrast enhanced CT and 18F-FDG PET/CT in suspicious recurrence of biliary tract cancer after curative resection.

Authors:  Yun-Gyoo Lee; Sae-Won Han; Do-Youn Oh; Eui Kyu Chie; Jin-Young Jang; Seock-Ah Im; Tae-You Kim; Sun-Whe Kim; Sung Whan Ha; Yung-Jue Bang
Journal:  BMC Cancer       Date:  2011-05-21       Impact factor: 4.430

Review 8.  The role of FDG-PET/CT in gynaecological cancers.

Authors:  Andrea G Rockall; Susan Cross; Sean Flanagan; Elizabeth Moore; Norbert Avril
Journal:  Cancer Imaging       Date:  2012-03-05       Impact factor: 3.909

Review 9.  Implications of the new FIGO staging and the role of imaging in cervical cancer.

Authors:  Aki Kido; Yuji Nakamoto
Journal:  Br J Radiol       Date:  2021-05-14       Impact factor: 3.629

Review 10.  Positron emission tomography alone, positron emission tomography-computed tomography and computed tomography in diagnosing recurrent cervical carcinoma: a systematic review and meta-analysis.

Authors:  Yi Xiao; Jia Wei; Yicheng Zhang; Weining Xiong
Journal:  Arch Med Sci       Date:  2014-05-13       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.